The Phenotyping Core will provide ORDRCC investigators with access to advanced high-content, cutting-edge biomolecular phenotyping services and datasets spanning genetic, genomic, proteomic, and functional cellular bioresponses on clinical samples available through the Clinical Characterization and Biorepository Core (CCBC) or from other ORDRCC Investigator projects. The tight integration of the Phenotyping Core and the CCBC within the ORDRCC enables both the efficient performance of phenotype characterizations and correlation of the clinical characteristics with molecular or cellular phenotypes on specific clinical samples. Consolidation of the range of technologies required for the complete characterization of a molecular or cellular phenotype into a single Core allows the Core to better assist all ORDRCC investigators in the efficient planning/design, execution and data analysis as dictated by their individual project needs. The Core is able to provide experience in performing research using clinical specimens, the necessary technical expertise in a wide range of molecular and bioassays, access to equipment and resources enabling cutting-edge approaches to address research questions, quality control assessment of the data collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations. Therefore, the goals of the Phenotyping Core can be summarized as follows: Goal 1: Offer expert consulting for experimental project design, cost analysis, implementation planning and project management for ORDRCC investigators. Goal 2: Provide access to advanced technology, centralized equipment and experienced personnel for high throughput/high content experimental phenotype characterization and biomarker assays in genetic, genomic, proteomic, immune phenotype and immune functional domains. Goal 3: Supply guidance on data quality control, processing of raw data, and preparation of data sets for more extensive statistical modeling. Goal 4: Assess and develop new cutting edge technologies for phenotype characterization.

Public Health Relevance

This Phenotyping Core provides ORDRCC investigators access to the technical expertise and resources to perform genetic, genomic, proteomic and cellular phenotype/function biomarker analyses required to develop a world class rheumatic disease focused clinical-translational research career.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oklahoma Medical Research Foundation
Oklahoma City
United States
Zip Code
Ratliff, Michelle L; Ward, Julie M; Merrill, Joan T et al. (2015) Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol 194:940-9
Freedman, Barry I; Langefeld, Carl D; Andringa, Kelly K et al. (2014) End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66:390-6
Ward, Julie M; Rose, Kira; Montgomery, Courtney et al. (2014) Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol 66:3404-12
Dozmorov, Mikhail G; Wren, Jonathan D; Alarcon-Riquelme, Marta E (2014) Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes. Epigenetics 9:276-85
Ritterhouse, Lauren L; Lu, Rufei; Shah, Hemangi B et al. (2014) Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European-American healthy controls. PLoS One 9:e94500
Young, K A; Terrell, D R; Guthridge, J M et al. (2014) Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 23:360-9
Guthridge, Joel M; Lu, Rufei; Sun, Harry et al. (2014) Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet 94:586-98
Munroe, Melissa E; Vista, Evan S; Guthridge, Joel M et al. (2014) Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 66:1888-99
James, Judith A (2014) Clinical perspectives on lupus genetics: advances and opportunities. Rheum Dis Clin North Am 40:413-32, vii
Kim-Howard, Xana; Sun, Celi; Molineros, Julio E et al. (2014) Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Hum Mol Genet 23:1656-68

Showing the most recent 10 out of 91 publications